A PHASE 1, NON-RANDOMIZED, OPEN-LABEL, SINGLE-DOSE, PARALLEL-COHORT STUDY TO COMPARE THE PHARMACOKINETICS OF PF 06865571 IN ADULT PARTICIPANTS WITH VARYING DEGREES OF HEPATIC IMPAIRMENT RELATIVE TO PARTICIPANTS WITHOUT HEPATIC IMPAIRMENT
Latest Information Update: 15 Apr 2021
At a glance
- Drugs Ervogastat (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Pharmacokinetics
- Sponsors Pfizer
Most Recent Events
- 30 Apr 2020 Status changed from recruiting to completed.
- 07 Apr 2020 Planned primary completion date changed from 28 Jun 2020 to 12 Apr 2020.
- 24 Oct 2019 Planned End Date changed from 14 Jun 2020 to 28 Jun 2020.